<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcitonin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcitonin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Calcitonin: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9182" href="/d/html/9182.html" rel="external">see "Calcitonin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11631" href="/d/html/11631.html" rel="external">see "Calcitonin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F144121"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Miacalcin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866167"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Calcimar</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1057074"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Hypercalcemia</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812485"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="623ef40c-b465-4034-b9a8-fb2518234261">Osteogenesis imperfecta</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteogenesis imperfecta:</b> Infants &gt;6 months, Children, and Adolescents: IM, SubQ: 2 units/kg/dose 3 times/week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-573785']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-573785'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729620"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F52729621"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F144125"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9182" href="/d/html/9182.html" rel="external">see "Calcitonin: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="329703b6-4d60-4f09-9777-3a31775700b5">Hypercalcemia, severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypercalcemia, severe (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in combination with other appropriate agents (ie, IV hydration, bisphosphonates) in patients with severe hypercalcemia (eg, symptomatic and albumin-corrected serum calcium &gt;14 mg/dL [&gt;3.5 mmol/L]) to rapidly reduce serum calcium while bisphosphonate therapy provides a long-term effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27170690','lexi-content-ref-Shane.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27170690','lexi-content-ref-Shane.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, SUBQ: </b>Initial: 4 units/kg every 12 hours; if calcium reduction is inadequate after 6 to 12 hours, may increase to 8 units/kg every 6 to 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27170690','lexi-content-ref-Shane.2022','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27170690','lexi-content-ref-Shane.2022','lexi-content-ref-manu.1'])">Ref</a></span>). Limit total duration of therapy to 24 to 48 hours due to tachyphylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36245251','lexi-content-ref-Shane.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36245251','lexi-content-ref-Shane.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="12f9a8e5-2e79-435b-8a69-e961250fab03">Osteoporosis, postmenopausal, fracture risk reduction or osteoporotic vertebral fracture pain relief</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, postmenopausal, fracture risk reduction (labeled use) or osteoporotic vertebral fracture pain relief (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used to reduce pain associated with acute osteoporotic vertebral fractures; switch to a more effective agent (eg, a bisphosphonate) once pain has abated. For fracture risk reduction, reserve use for patients in whom alternative agents are contraindicated or cannot be taken due to limited efficacy compared to other therapies; ensure adequate calcium and vitamin D intake during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32427503','lexi-content-ref-30907953','lexi-content-ref-Rosen.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32427503','lexi-content-ref-30907953','lexi-content-ref-Rosen.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, SUBQ:</b> 100 units once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1818759','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1818759','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intranasal: </b>200 units (1 spray) in <b>one nostril</b> once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9385283','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9385283','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e26968cd-a76e-40af-abcf-7737ae0dba16">Paget disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paget disease (alternative agent):</b>
<b>IM, SUBQ:</b> 100 units daily; dosage range: 50 to 100 units administered 3 to 7 days per week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4857531','lexi-content-ref-7000081','lexi-content-ref-1933617','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4857531','lexi-content-ref-7000081','lexi-content-ref-1933617','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991712"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Calcitonin levels are elevated in patients with chronic kidney disease (CKD), either because of decreased metabolism by the kidney or increased secretion; however, the clinical implications of this are unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-474191','lexi-content-ref-331128']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-474191','lexi-content-ref-331128'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injectable, intranasal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24726630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24726630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24726630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24726630'])">Ref</a></span>). Consider use in conjunction with guidance from the patient’s nephrology team, as disorders of calcium homeostasis and bone metabolism can be difficult to distinguish from CKD mineral and bone disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not likely to be significantly dialyzable (high molecular weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>): Dose as for eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis: </b>Not likely to be significantly dialyzable (high molecular weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>): Dose as for eGFR &lt;30 mL/minute/1.73 m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.dor']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.dor'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989033"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F144091"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults. Unless otherwise noted, frequencies reported are with nasal spray.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (injection: ~50%; nasal spray: 69%; drug efficacy can be affected)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Facial flushing (injection: 2% to 5%), flushing of hands and feet (injection: 2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythematous rash (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1% to 3%), nausea (injection: 10%; nasal spray: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy (1% to 3%), malignant neoplasm (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site (injection: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (1% to 3%), dizziness (1% to 3%), paresthesia (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (5%), myalgia (1% to 3%), osteoarthritis (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal lacrimation (1% to 3%), conjunctivitis (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (1% to 3%), epistaxis (4%), flu-like symptoms (1% to 3%), sinusitis (2%), upper respiratory tract infection (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all routes):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, edema, facial edema, flushing, hypertension, pedal edema, peripheral edema, syncope, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, dermatitis, diaphoresis, earlobe pruritus, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia, hypocalcemia tetany</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Ageusia, decreased appetite, diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Casts in urine, nocturia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, hypersensitivity reaction (including severe hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anosmia, fatigue, headache, salty taste, seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, musculoskeletal pain, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Eye pain, visual disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F144106"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to calcitonin salmon or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F144088"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Salmon-derived products: Anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat have been reported; have epinephrine immediately available for a possible hypersensitivity reaction. A skin test should be performed prior to initiating therapy of calcitonin salmon in patients with suspected sensitivity; a detailed skin testing protocol is available from the manufacturer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypocalcemia: Hypocalcemia with tetany and seizure activity has been reported. Hypocalcemia and other disorders affecting mineral metabolism (eg, vitamin D deficiency) should be corrected before initiating therapy; monitor serum calcium and symptoms of hypocalcemia during therapy. Administer in conjunction with calcium and vitamin D when treating Paget disease or postmenopausal osteoporosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Analyses of randomized controlled trials (in osteoporosis and osteoarthritis) using the nasal spray and oral formulations have demonstrated a statistically significant increase in the risk of the development of cancer in calcitonin-treated patients (compared to placebo). The risk for malignancies is associated with long-term use of calcitonin (trials ranged from 6 months to 5 years in duration). Periodically reassess continued use of calcitonin therapy, carefully considering the risks versus benefits. Similar risk for other routes (subcutaneous, IM, IV) cannot be ruled out.</p>
<p style="text-indent:-2em;margin-left:4em;">• Urinary sediment abnormalities: Coarse granular casts and casts containing renal tubular epithelial cells were observed following use in young adults on bed rest during a study to examine the effect of immobilization on osteoporosis; no other renal abnormalities were reported and sediment normalized after discontinuation; consider monitoring urine sediment periodically; however, the clinical significance of this finding is unknown.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis: Risk vs benefit: Fracture reduction efficacy has not been demonstrated; use has not been shown to increase spinal bone mineral density in early postmenopausal patients (eg, ≤5 years postmenopause). Use should be reserved for postmenopausal patients for whom alternative treatments are not suitable (eg, patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). Consider potential benefits of therapy against risks, including the potential risk for malignancy with long-term use. Short-term treatment may provide analgesic effect in patients with acute painful vertebral fractures (AACE/ACE [Camacho 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Nasal spray: Rhinitis and epistaxis have been reported; mucosal alterations may occur. Temporarily withdraw use if ulceration of nasal mucosa occurs. Discontinue for severe ulcerations &gt;1.5 mm, those that penetrate below the mucosa, or those associated with heavy bleeding. Patients &gt;65 years of age may experience a higher incidence of nasal adverse events with calcitonin nasal spray.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Antibody formation to calcitonin-salmon has been reported with the injection and nasal spray. Consider the possibility of antibody formation in patients who initially respond to therapy but later do not respond to treatment.</p></div>
<div class="block foc drugH1Div" id="F144099"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Miacalcin: 200 units/mL (2 mL) [contains phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 units/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 units/actuation (3.7 mL)</p></div>
<div class="block geq drugH1Div" id="F144084"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F144108"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Calcitonin (Salmon) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 units/mL (per mL): $1,878.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Calcitonin (Salmon) Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 units/ACT (per mL): $32.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Miacalcin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 units/mL (per mL): $1,879.26</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866168"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calcimar: 200 units/mL (2 mL) [contains phenol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 200 units/mL (2 mL)</p></div>
<div class="block admp drugH1Div" id="F52612341"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Intranasal: Before first use, allow bottle to reach room temperature, then prime pump by releasing at least 5 sprays until full spray is produced. To administer, place nozzle into nostril with head in upright position. Spray into <b>one</b> nostril daily; alternate nostrils to reduce irritation. Do not prime pump before each daily use. Discard after 30 doses. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Parenteral: May be administered SubQ or IM; do not exceed 2 mL volume per injection site; SubQ is preferred for outpatient self administration unless the injection volume is &gt;2 mL; IM is preferred  if the injection volume is &gt;2 mL (use multiple injection sites if dose volume is &gt;2 mL). </p></div>
<div class="block adm drugH1Div" id="F144103"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: May be administered IM or SUBQ. IM route is preferred if the injection volume is &gt;2 mL (use multiple injection sites if dose volume is &gt;2 mL). SUBQ route is preferred for outpatient self-administration unless the injection volume is &gt;2 mL.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasal spray: Before first use, allow bottle to reach room temperature, then prime pump by releasing until a full spray is produced. To administer, place nozzle into nostril with head in upright position. Alternate nostrils daily. Do not prime pump before each daily use. Discard after 30 doses.</p></div>
<div class="block sts drugH1Div" id="F144116"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vial under refrigeration at 2°C to 8°C (36°F to 46°F); protect from freezing. The following stability information has also been reported: May be stored at room temperature for up to 14 days (Cohen 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">Nasal: Store unopened bottle under refrigeration at 2°C to 8°C (36°F to 46°F); do not freeze. After opening, store for up to 35 days at room temperature of 20°C to 25°C (68°F to 77°F). Store in upright position.</p></div>
<div class="block usep drugH1Div" id="F53565785"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Parenteral: Treatment of Paget's disease of bone; adjunctive therapy for hypercalcemia; postmenopausal osteoporosis (FDA approved in adults); has also been used for osteogenesis imperfecta </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Intranasal: Postmenopausal osteoporosis in women &gt;5 years postmenopause with low bone mass (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F144173"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Calcitonin may be confused with calcitriol </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fortical may be confused with Foradil</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Miacalcin may be confused with Micatin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Calcitonin nasal spray is administered as a single spray into <b>one</b> nostril daily, using alternate nostrils each day.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298928"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6218757"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Calcitonin may decrease the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zoledronic Acid: Calcitonin may enhance the hypocalcemic effect of Zoledronic Acid. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F144110"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Patients with Paget's disease and hypercalcemia should follow a low calcium diet as prescribed. Recommended amounts of vitamin D and calcium intake is essential for preventing/treating osteoporosis. If dietary intake is inadequate, dietary supplementation is recommended. Patients should consume:</p>
<p style="text-indent:-2em;margin-left:2em;">Calcium: 1,000 mg/day (males: 50 to 70 years of age) <b>or</b> 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D: 800 to 1,000 units/day (age ≥50 years) (NOF [Cosman 2014]). Recommended dietary allowance (RDA): 600 units/day (age ≤70 years) <b>or</b> 800 units/day (age ≥71 years) (IOM 2011).</p></div>
<div class="block pri drugH1Div" id="F1861980"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Endogenous calcitonin does not cross the placenta (Dochez 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of calcitonin for the treatment of hypercalcemia (Bilezikian 2022; Koren 2018; Krysiak 2011; Richa 2018) or other indications during pregnancy (Kovacs 2016; O’Regan 2001; Turek 2012) are limited. Postpartum use of calcitonin for the treatment of pregnancy associated osteoporosis has been described (Kovacs 2015; Ozturk 2014; Stumpf 2007).</p></div>
<div class="block mopp drugH1Div" id="F53565775"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum electrolytes and calcium; alkaline phosphatase and 24-hour urine collection for hydroxyproline excretion (Paget's disease); urinalysis (urine sediment); serum calcium; periodic nasal exams (intranasal use only)</p></div>
<div class="block pha drugH1Div" id="F144087"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Peptide sequence similar to human calcitonin; functionally antagonizes the effects of parathyroid hormone. Directly inhibits osteoclastic bone resorption; promotes the renal excretion of calcium, phosphate, sodium, magnesium, and potassium by decreasing tubular reabsorption; increases the jejunal secretion of water, sodium, potassium, and chloride</p></div>
<div class="block phk drugH1Div" id="F144105"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypercalcemia: IM, SUBQ: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Paget's disease: Within a few months; may take up to 1 year for neurologic symptom improvement.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Hypercalcemia: IM, SUBQ: 6 to 8 hours; following multiple doses, hypercalcemic effect diminishes within 24 to 48 hours (Nilsson 1978; Stevenson 1988).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Intranasal: Rapidly but highly variable and lower than IM administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.15 to 0.3 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized in kidneys, blood, and peripheral tissue.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: IM: 66%; SUBQ: 71%; Nasal: ~3% to 5% (relative to IM).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination (terminal): IM: 58 minutes; SUBQ: 59 to 64 minutes; Nasal: ~18 to 23 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: SUBQ: ~23 minutes; Nasal: ~10 to 13 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as inactive metabolites).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Salmon calcitonin: 3.1 mL/kg/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F144111"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Calcitonin | Miacalcic</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Calcitonina sandoz | Citonina | Osmil | Salmocalcin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Calcitonin | Ucecal</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Calsynar | Miacalcic</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Neocalcin | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acticalcin | Calsynar | Miacalcic | Seacalcit | Serocalcin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Calcitonin Sandoz | Cibacalcin | Miacalcic | Miacalcic mite</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Calnisan | Calsynar | Miacalcic | Osteociton</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bang rui de | Calcitonin (salmon) | Calco | Han xin | Jin er li | Ka xi meng | Miacalcic | Salcatonin | Salmon calcitonin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Calsynar | Miacalcic | Porostenina | Salmical</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Osteodon | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Calcitonin | Calcitonin CT | Calcitonin Sandoz | Karil | Miacalcic</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Calcitonina | Miacalcic</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Calnisan | Miacalcic | Porostenina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Karil | Miacalcic</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Apo calcitonin | Boninasal | Miacalcic</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bionocalcin | Calcitonina almirall | Calcitonina hubber | Calogen | Calsynar | Kalsimin | Miacalcic | Oseototal | Ospor | Osteobion | Sical | Tonocaltin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Riostin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Calsynar | Miacalcic</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alciton | Alicitonin | Assocals | Aurocalcin | Brosidon | Calci-10 | Calcicontrol | Calcideron | Calciphar | Calciplus | Calcispren | Calciton | Calcitonin/Alice loren | Calcitonin/Target | Calco | Caloston | Calsaton | Calsynar | Caltec | Crocalcin | Doctadryl | Farmicalcine | Genecalcin | Iricalcin | Latonina | Miacalcic | Miadenil | Mioser | Neostesin | Nopremin | Norcalcin | Nylex | Osivan | Ostifix | Ostoplus | Ostosalm | Pluston | Rafacalcin | Rothrin | Sal-Cal | Salcatol | Salmocalcin | Salmoten | Tendolon | Tonocalcin | Tosicalcin | Transcalcium | Velcacalcin | Zyoston</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo calcitonin | Miacalcic | Osteocalcin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Biostin | Calco | Miacalcic</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bmd rise | Bonspark | Calcinase | Calnasal | Calspray | Citonap | Gemcal | Maxtonin | Miacalcic | Salmoncal | Uptonin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Biocalcin | Calciben | Calciosint | Calcitonina armour | Calcitonina sandoz | Catonin | Miacalcic | Osteocalcin | Osteotonina | Osteovis | Rulicalcin | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Calco | Miacalcic | Rafacalcin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Calcitoran | Leton | Leton tobishi | Marincatonil | Sakecalton | Sakecitonin | Sakecitonin sawai | Salmostone | Salmotonin aventis | Sarcalnin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Biocalcin | Boncalmon | Calcidol | Caltonin | Menocal | Miacalcic | Steocin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Calco | Miacalcic | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Calsynar | Cibacalcin | Miacalcic</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Oseum | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Osteocalcin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Calcit-s | Calciton | Miacalcic</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Calcitonin | Miacalcic | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Eurocalcin | Miacalcic | Salmocal</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Calcimar | Calcitonin Salmon | Miacalcin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bionocalcin | Calcimon | Calcitonina de salmao | Calogen | Calsyn | Miacalcic | Osseocalcina | Osteodon | Ostosalm | Salcat | Tonocaltin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Calcitonina sandoz | Caltonin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alostin | Miacalcic | Veprena</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Calcitec | Miacalcic</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Osteocalcin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic | Osteodon</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Calciton | Miacalcic | Osteodon | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cadotin | Calci-10 | Calco | Miacalcic | Miacalcic nasal | Osteocalcin | Salmocin | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Calcitonina hubber | Calsynar | Miacalcic | Nylex | Steocin | Tonocalcin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cadotin | Calcinin | Calco | Calsynar | Menocal | Miacalcic | Steocin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Calcitonin ratiopharm | Miacalcic</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Calsynar | Miacalcic | Salmocalcin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Caltanid | Miacalcic | Osteociton | Porostenina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Miacalcic</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Calbio</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-5083377">
<a name="5083377"></a>Bergqvist E, Sjoberg HE, Hjern B, et al. Calcitonin in the Treatment of Hypercalcaemic Crisis. <i>Acta Med Scand</i>. 1972;192(5):385-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/5083377/pubmed" id="5083377" target="_blank">5083377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8263125">
<a name="8263125"></a>Bilezikian JP. Clinical review 51: Management of hypercalcemia. <i>J Clin Endocrinol Metab</i>. 1993;77(6):1445-1449. doi:10.1210/jcem.77.6.8263125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/8263125/pubmed" id="8263125" target="_blank">8263125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36245251">
<a name="36245251"></a>Bilezikian JP, Khan AA, Silverberg SJ, et al; International Workshop on Primary Hyperparathyroidism. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. <i>J Bone Miner Res</i>. 2022;37(11):2293-2314. doi:10.1002/jbmr.4677<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/36245251/pubmed" id="36245251" target="_blank">36245251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3788423">
<a name="3788423"></a>Bucht E, Telenius-Berg M, Lundell G, Sjöberg HE. Immunoextracted calcitonin in milk and plasma from totally thyroidectomized women. Evidence of monomeric calcitonin in plasma during pregnancy and lactation. <i>Acta Endocrinol (Copenh)</i>. 1986;113(4):529-535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/3788423/pubmed" id="3788423" target="_blank">3788423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Par.1">
<a name="Par.1"></a>Calcitonin salmon nasal spray [prescribing information]. Woodcliff Lake, NJ; Par Pharmaceutical; March 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27643923">
<a name="27643923"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2016: executive summary. <i>Endocr Pract</i>. 2016;22(9):1111-1118. doi:10.4158/EP161435.ESGL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/27643923/pubmed" id="27643923" target="_blank">27643923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):1-46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-573785">
<a name="573785"></a>Castells S, Colbert C, Chakrabarti C, et al. Therapy of Osteogenesis Imperfecta With Synthetic Salmon Calcitonin. <i>J Pediatr</i>. 1979;95(5, pt 1):807-811.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/573785/pubmed" id="573785" target="_blank">573785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17687059">
<a name="17687059"></a>Cohen V, Jellinek SP, Teperikidis L, et al. Room-Temperature Storage of Medications Labeled for Refrigeration. <i>Am J Health-Syst Pharm</i>. 2007;64(16):1711-1715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/17687059/pubmed" id="17687059" target="_blank">17687059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4857531">
<a name="4857531"></a>DeRose J, Singer FR, Avramides A, et al. Response of Paget’s disease to porcine and salmon calcitonins. <i>Am J Med</i>. 1974;56(6):858-866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/4857531/pubmed" id="4857531" target="_blank">4857531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25367603">
<a name="25367603"></a>Dochez V, Ducarme G. Primary hyperparathyroidism during pregnancy. <i>Arch Gynecol Obstet</i>. 2015;291(2):259-263.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/25367603/pubmed" id="25367603" target="_blank">25367603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.dor">
<a name="expert.dor"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27170690">
<a name="27170690"></a>Goldner W. Cancer-related hypercalcemia. <i>J Oncol Pract</i>. 2016;12(5):426-432. doi:10.1200/JOP.2016.011155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/27170690/pubmed" id="27170690" target="_blank">27170690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine). <i>Dietary Reference Intakes for Calcium and Vitamin D.</i> The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7709605">
<a name="7709605"></a>Koldovský O. Hormones in milk. <i>Vitam Horm</i>. 1995;50:77-149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/7709605/pubmed" id="7709605" target="_blank">7709605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29694631">
<a name="29694631"></a>Koren R, Neeman O, Koren S, Benbassat CA. Humoral hypercalcemia of pregnancy treated with bisphosphonates. <i>Arch Endocrinol Metab</i>. 2018;62(1):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/29694631/pubmed" id="29694631" target="_blank">29694631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26887676">
<a name="26887676"></a>Kovacs CS. Maternal mineral and bone metabolism during pregnancy, lactation, and post-weaning recovery. <i>Physiol Rev</i>. 2016;96(2):449-547. doi:10.1152/physrev.00027.2015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/26887676/pubmed" id="26887676" target="_blank">26887676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25939309">
<a name="25939309"></a>Kovacs CS, Ralston SH. Presentation and management of osteoporosis presenting in association with pregnancy or lactation. <i>Osteoporos</i>
<i>Int</i>. 2015;26(9):2223-2241. doi:10.1007/s00198-015-3149-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/25939309/pubmed" id="25939309" target="_blank">25939309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20848117">
<a name="20848117"></a>Krysiak R, Wilk M, Okopien B. Recurrent pancreatitis induced by hyperparathyroidism in pregnancy. <i>Arch Gynecol Obstet</i>. 2011;284(3):531-534.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/20848117/pubmed" id="20848117" target="_blank">20848117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9385283">
<a name="9385283"></a>Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. <i>Acta Orthop Scand Suppl</i>. 1997;275:112-114. doi:10.1080/17453674.1997.11744761<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/9385283/pubmed" id="9385283" target="_blank">9385283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1818759">
<a name="1818759"></a>Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. <i>Calcif Tissue Int</i>. 1991;49(6):369-372. doi:10.1007/BF02555844<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/1818759/pubmed" id="1818759" target="_blank">1818759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alcami.1">
<a name="Alcami.1"></a>Miacalcin injection (calcitonin-salmon) [prescribing information]. Charleston, SC: Alcami Corporation; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.1">
<a name="Novartis.1"></a>Miacalcin nasal spray (calcitonin-salmon) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24726630">
<a name="24726630"></a>Miller PD. Bone disease in CKD: a focus on osteoporosis diagnosis and management. <i>Am J Kidney Dis</i>. 2014;64(2):290-304. doi:10.1053/j.ajkd.2013.12.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/24726630/pubmed" id="24726630" target="_blank">24726630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-474191">
<a name="474191"></a>Nielsen HE, Christensen CK, Olsen KJ. Serum calcitonin in patients with chronic renal disease. <i>Acta Med Scand</i>. 1979;205(7):615-618. doi:10.1111/j.0954-6820.1979.tb06114.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/474191/pubmed" id="474191" target="_blank">474191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-358762">
<a name="358762"></a>Nilsson O, Almqvist S, Karlberg BE. Salmon calcitonin in the acute treatment of moderate and severe hypercalcemia in man. <i>Acta Med Scand</i>. 1978;204(4):249-252.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/358762/pubmed" id="358762" target="_blank">358762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11709690">
<a name="11709690"></a>O'Regan EM, Gibb DH, Odell EW. Rapid growth of giant cell granuloma in pregnancy treated with calcitonin. <i>Oral Surg Oral Med Oral Pathol Oral Radiol</i>
<i>Endod</i>. 2001;92(5):532-538. doi:10.1067/moe.2001.119246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/11709690/pubmed" id="11709690" target="_blank">11709690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24102815">
<a name="24102815"></a>Ozturk C, Atamaz FC, Akkurt H, Akkoc Y. Pregnancy-associated osteoporosis presenting severe vertebral fractures. <i>J Obstet Gynaecol Res</i>. 2014;40(1):288-292. doi:10.1111/jog.12157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/24102815/pubmed" id="24102815" target="_blank">24102815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pontiroli.1">
<a name="Pontiroli.1"></a>Pontiroli AE, Pajetta E, Scaglia L, et al. Analgesic Effect of Intranasal and Intramuscular Salmon Calcitonin in Postmenopausal Osteoporosis: A Double-Blind, Double-Placebo Study. <i>Aging (Milano).</i> 1994;6(6):459-463.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30803025">
<a name="30803025"></a>Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget's disease of bone in adults: a clinical guideline. <i>J Bone Miner Res</i>. 2019;34(4):579-604. doi:10.1002/jbmr.3657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/30803025/pubmed" id="30803025" target="_blank">30803025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7733123">
<a name="7733123"></a>Reginster JY, Deroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. <i>Am J Med.</i> 1995;98(5):452-458.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/7733123/pubmed" id="7733123" target="_blank">7733123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8256795">
<a name="8256795"></a>Reginster JY. Calcitonin for prevention and treatment of osteoporosis. <i>Am J Med.</i> 1993;95(5A):44S-47S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/8256795/pubmed" id="8256795" target="_blank">8256795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29623207">
<a name="29623207"></a>Richa CG, Saad KJ, Chaaban AK, El Rawas MS. A rare case of hypercalcemia-induced pancreatitis in a first trimester pregnant woman. <i>Endocrinol Diabetes Metab Case Rep</i>. 2018;pii: 17-0175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/29623207/pubmed" id="29623207" target="_blank">29623207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.1">
<a name="Rosen.1"></a>Rosen HN. Calcitonin in the prevention and treatment of osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed April 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shane.2022">
<a name="Shane.2022"></a>Shane E. Treatment of hypercalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-331128">
<a name="331128"></a>Silva OL, Becker KL, Shalhoub RJ, Snider RH, Bivins LE, Moore CF. Calcitonin levels in chronic renal disease. <i>Nephron</i>. 1977;19(1):12-18. doi:10.1159/000180860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/331128/pubmed" id="331128" target="_blank">331128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25406796">
<a name="25406796"></a>Singer FR, Bone HG 3rd, Hosking DJ, et al; Endocrine Society. Paget's disease of bone: an Endocrine Society clinical practice guideline.<i> J Clin Endocrinol Metab</i>. 2014;99(12):4408-4422. doi:10.1210/jc.2014-2910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/25406796/pubmed" id="25406796" target="_blank">25406796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1933617">
<a name="1933617"></a>Singer FR. Clinical efficacy of salmon calcitonin in Paget's disease of bone. <i>Calcif Tissue Int</i>. 1991;49(suppl 2):S7-S8. doi:10.1007/BF02561369<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/1933617/pubmed" id="1933617" target="_blank">1933617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7000081">
<a name="7000081"></a>Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. <i>Arthritis</i>
<i>Rheum</i>. 1980;23(10):1148-1154. doi:10.1002/art.1780231012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/7000081/pubmed" id="7000081" target="_blank">7000081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3053127">
<a name="3053127"></a>Stevenson JC. Current management of malignant hypercalcemia. <i>Drugs.</i> 1988;36(2):229-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/3053127/pubmed" id="3053127" target="_blank">3053127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18217397">
<a name="18217397"></a>Stumpf UC, Kurth AA, Windolf J, Fassbender WJ. Pregnancy-associated osteoporosis: an underestimated and underdiagnosed severe disease. A review of two cases in short- and long-term follow-up. <i>Adv Med Sci</i>. 2007;52:94-97.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/18217397/pubmed" id="18217397" target="_blank">18217397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23230038">
<a name="23230038"></a>Turek T, Wigton A. Calcitonin for phantom limb pain in a pregnant woman. <i>Am J Health Syst Pharm</i>. 2012;69(24):2149-2152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcitonin-pediatric-drug-information/abstract-text/23230038/pubmed" id="23230038" target="_blank">23230038</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13106 Version 225.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
